Design Therapeutics Q2 net loss narrower than expected
DSGN•Outlook and analyst coverage
- Company expects to share 12-week RESTORE-FA trial data in Q1 2027
- Design to provide update on RESTORE-FA registrational plans in Q4 2026
- Company anticipates reporting DM1 and FECD trial data in 2027
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell".
The average consensus recommendation for the biotechnology & medical research peer group is "buy".
Wall Street's median 12-month price target for Design Therapeutics Inc is $21.00, about 72.4% above its July 31 closing price of $12.18.
Pipeline updates and trial timing
- CLINICAL TRIAL PROGRESS - Co cited positive four-week data from RESTORE-FA trial in Friedreich ataxia and modifications to support next-stage development
- PIPELINE ADVANCEMENT - Patient dosing began in Phase 1 trial of DT-818 for myotonic dystrophy type 1
- PROGRAM DELAYS - FECD trial data now expected in 2027 due to supply delay of DT-168 eye droppers
Q2 results came in ahead of expectations
- US biotech firm's Q2 net loss was lower than analyst expectations
- Operating expenses for Q2 totaled $22.2 mln
- Company ended Q2 with $207.4 mln in cash and securities
